BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 21507186)

  • 1. Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges.
    Manfredi C; Ditonno F; Franco A; Bologna E; Licari LC; Arcaniolo D; Tubaro A; De Nunzio C; Antonelli A; De Sio M; Cherullo EE; Autorino R
    Curr Oncol Rep; 2023 Dec; 25(12):1431-1443. PubMed ID: 37910274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases.
    Zhang Y; Zhang Y; Shi M; Liu X; Zhang H; Zhao P; Ren G
    Am J Clin Exp Urol; 2024; 12(2):100-109. PubMed ID: 38736618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cuproptosis-related genes for predicting the development of prostate cancer.
    Wang X; Chen X; Xu C; Zhou W; Wu D
    Open Med (Wars); 2023; 18(1):20230717. PubMed ID: 37711156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
    Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies.
    Men T; Yu C; Wang D; Liu F; Li J; Qi X; Yang C; Jiang W; Wei X; Li X; Wang B; Mi J; Tian G
    Oncotarget; 2017 Jul; 8(28):45994-46005. PubMed ID: 28526808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race as an independent predictor of outcome after treatment for localized prostate cancer.
    Sohayda CJ; Kupelian PA; Altsman KA; Klein EA
    J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
    Coard KC; Skeete DH
    BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and histopathological characteristics of familial prostate cancer in Finland.
    Pakkanen S; Kujala PM; Ha N; Matikainen MP; Schleutker J; Tammela TL
    BJU Int; 2012 Feb; 109(4):557-63. PubMed ID: 21507186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.